ASCO Genitourinary Cancers Symposium 2025

Advanced GU Oncology Updates in Prostate, Bladder, Renal & Testicular Cancer (Videos + Slides + Posters)

The ASCO Genitourinary Cancers Symposium 2025 represents one of the most important global meetings in modern genitourinary oncology, bringing together leading experts in medical oncology, urologic surgery, radiation oncology, molecular diagnostics, translational research, and precision cancer therapeutics. The symposium delivers a highly focused review of the latest scientific discoveries, practice-changing clinical trials, biomarker innovations, and multidisciplinary treatment strategies shaping the future of GU cancer care.

Held February 13–15, 2025, the meeting explores rapidly evolving areas across:

• Prostate cancer
• Urothelial carcinoma
• Renal cell carcinoma (RCC)
• Testicular cancer
• Penile and urethral malignancies
• Radioligand therapy
• ctDNA technologies
• Immunotherapy resistance
• Antibody-drug conjugates (ADCs)
• Precision oncology and biomarker-guided treatment

This educational package includes:

• Oncology videos
• Presentation slides
• Scientific posters
• Oral abstract sessions
• Rapid abstract discussions
• Case-based multidisciplinary panels
• Trials-in-progress presentations

The symposium emphasizes not only emerging therapeutics, but also the increasingly complex clinical reasoning required in modern oncology practice.

---

Why Genitourinary Oncology Is Rapidly Evolving

GU oncology has become one of the fastest-changing areas in cancer medicine.

Clinical management increasingly depends on:

• Molecular profiling
• Genomic biomarkers
• ctDNA monitoring
• Radioligand therapies
• Combination immunotherapy
• Precision radiation strategies
• Targeted systemic treatment
• Advanced imaging integration

At the same time, clinicians face growing complexity involving:

• Treatment sequencing
• Resistance mechanisms
• Biomarker interpretation
• Toxicity management
• Functional outcomes
• Survivorship issues
• Patient quality of life

The ASCO GU Symposium stands out because it successfully integrates cutting-edge science with real-world multidisciplinary cancer management.

---

Prostate Cancer

Radioligand Therapy, mCRPC & Advanced Precision Oncology

Prostate cancer remains one of the central themes throughout ASCO GU 2025.

The symposium reviews:

• Metastatic hormone-sensitive prostate cancer (mHSPC)
• Metastatic castration-resistant prostate cancer (mCRPC)
• Advanced androgen receptor pathway inhibitors (ARPIs)
• PSMA-targeted radioligand therapy
• Salvage treatment strategies
• ctDNA applications
• Oligometastatic disease management
• Radiation response biomarkers

Major presentations include updates from:

• TALAPRO-2
• ENZA-p
• PSMAfore
• STAMPEDE
• WOLVERINE

The sessions highlight how radioligand therapy is increasingly moving into earlier stages of advanced prostate cancer management. Discussions explore:

• Combination treatment sequencing
• Imaging response assessment
• Survival outcomes
• Quality-of-life implications
• ctDNA monitoring during therapy

One especially important educational theme involves determining which patients derive the greatest benefit from:

• ARPIs
• Radioligand therapies
• Metastasis-directed treatment
• Salvage interventions

rather than applying uniform treatment strategies to all patients.

---

Oligometastatic Prostate Cancer & Personalized Treatment Intensification

The symposium also provides substantial focus on:

Oligometastatic prostate cancer

This remains a rapidly evolving area where clinical decision-making is particularly nuanced.

Discussions examine:

• Radiation therapy integration
• Systemic therapy escalation
• Genetics and genomic risk
• Imaging advances
• Patient selection for metastasis-directed therapy

The WOLVERINE meta-analysis and related presentations offer valuable insight into evolving evidence supporting personalized treatment intensification strategies in oligometastatic disease.

---

Bladder Cancer & Urothelial Carcinoma

Immunotherapy, ADCs & ctDNA Innovations

Bladder cancer sessions represent another major strength of the meeting.

The symposium reviews:

• Muscle-invasive bladder cancer (MIBC)
• Non-muscle invasive bladder cancer (NMIBC)
• Perioperative immunotherapy
• Antibody-drug conjugates
• FGFR inhibitors
• HER2-targeted therapies
• ctDNA surveillance
• BCG-unresponsive disease

Major studies discussed include:

• CheckMate 274
• NIAGARA
• EV-302
• RETAIN-2
• RC48-C017

One of the most clinically important themes involves:

Antibody-Drug Conjugates (ADCs)

The symposium explores:

• Nectin-4 targeted ADCs
• HER2-directed therapies
• Novel combination regimens
• Toxicity management
• Mechanisms of resistance

As bladder cancer therapeutics rapidly expand, clinicians increasingly require sophisticated understanding of:

• Molecular selection
• Biomarker interpretation
• Treatment sequencing
• Immunotherapy combinations
• Long-term toxicity considerations

---

ctDNA & Molecular Residual Disease Monitoring

A particularly high-yield component of ASCO GU 2025 focuses on:

Circulating tumor DNA (ctDNA)

Dedicated sessions examine how ctDNA may influence:

• Clinical staging
• Early recurrence detection
• Perioperative management
• Minimal residual disease assessment
• Adjuvant therapy selection

In practice, ctDNA technologies may significantly reshape bladder cancer management over the coming years.

The symposium appropriately balances enthusiasm for these technologies with discussion of:

• Current limitations
• Standardization challenges
• Clinical applicability
• Interpretation complexity

---

Renal Cell Carcinoma (RCC)

Immunotherapy Resistance & Biomarker Development

Renal oncology discussions focus heavily on:

• Combination immunotherapy
• Targeted therapies
• Biomarker evolution
• ctDNA applications
• Adjuvant therapy
• Rare RCC subtypes
• Resistance mechanisms

Major studies reviewed include:

• COSMIC-313
• CheckMate 9ER
• KEYMAKER-U03
• CALYPSO
• ARC-20

The sessions repeatedly address one of the most difficult modern RCC questions:

What happens when immunotherapy fails?

This represents a growing clinical challenge as more patients eventually develop:

• Acquired resistance
• Toxicity limitations
• Progression after combination therapy
• Biomarker uncertainty

The multidisciplinary case-based discussions provide nuanced insight into how experts approach increasingly complex post-immunotherapy treatment decisions.

---

Biomarkers & Precision Oncology in RCC

The symposium also provides extensive discussion on:

• KIM-1 biomarkers
• Molecular prognostic tools
• ctDNA analysis
• Predictive biomarkers
• Precision treatment selection

One especially thoughtful session examines whether biomarkers in RCC represent:

• A true clinical turning point
  or
• Another area of overpromised precision medicine

This balanced scientific approach is one of the meeting’s strongest educational features.

---

Testicular Cancer & Germ Cell Tumors

The germ cell tumor sessions review:

• Seminoma management
• High-dose chemotherapy
• Retroperitoneal lymph node dissection
• Refractory germ cell tumors
• Novel investigational therapies

Although testicular cancer represents a smaller proportion of GU oncology, management decisions remain highly specialized and clinically important because of:

• Curative treatment potential
• Long-term survivorship
• Treatment toxicity considerations
• Young patient populations

---

Penile, Urethral & Rare GU Malignancies

Rare GU cancers often receive limited educational attention elsewhere.

ASCO GU 2025 includes focused updates on:

• Penile carcinoma
• Urethral malignancies
• Adrenal tumors
• Rare GU histologies

The symposium appropriately highlights the importance of:

• Multidisciplinary collaboration
• Translational research
• Specialized referral centers
• Clinical trial participation

in these rare but clinically challenging cancers.

---

Translational Research & Precision Cancer Medicine

One of the defining strengths of the symposium is its integration of:

• Translational oncology
• Molecular diagnostics
• Biomarker science
• Genomic profiling
• Precision treatment strategies

The sessions repeatedly explore how:

• ctDNA
• molecular classifiers
• predictive biomarkers
• tumor genomics
• resistance mechanisms

are increasingly shaping the future of GU oncology care.

---

What’s Included

• Oncology video lectures
• Educational presentation slides
• Scientific posters
• Oral abstract sessions
• Rapid oral presentations
• Case-based multidisciplinary panels
• Trials-in-progress discussions
• Prostate cancer updates
• Bladder cancer immunotherapy sessions
• RCC biomarker and immunotherapy reviews
• Radioligand therapy education
• ctDNA and precision oncology updates
• Germ cell tumor management discussions

---

Who Benefits Most From This Symposium

This program is especially valuable for:

• Medical oncologists
• Urologic oncologists
• Radiation oncologists
• Urologists
• GU oncology fellows
• Translational cancer researchers
• Advanced practice oncology providers

It is particularly useful for clinicians seeking:

• Practice-changing oncology trials
• Precision GU oncology updates
• Immunotherapy sequencing strategies
• ctDNA and biomarker education
• Radioligand therapy reviews
• Multidisciplinary cancer management approaches

---

Final Expert Perspective

The ASCO Genitourinary Cancers Symposium 2025 stands out because it captures the extraordinary pace of innovation currently transforming genitourinary oncology.

By combining late-breaking clinical trials, radioligand therapy, immunotherapy advances, antibody-drug conjugates, biomarker science, ctDNA technologies, and multidisciplinary case-based management into one highly specialized educational meeting, ASCO GU 2025 provides one of the most clinically relevant and scientifically advanced reviews available in modern GU cancer medicine.

For clinicians involved in prostate cancer, bladder cancer, RCC, and advanced genitourinary oncology, this symposium offers an exceptionally valuable update on the therapies, technologies, and precision medicine strategies most likely to influence oncology practice in the years ahead.